infect
one
four
serotyp
dengu
viru
dv
member
flavivirida
famili
caus
wide
spectrum
clinic
manifest
although
major
symptomat
patient
develop
febril
ill
known
dengu
fever
df
nonspecif
symptom
headach
fever
myalgia
around
patient
develop
sever
form
diseas
sever
dengu
sd
may
includ
plasma
leakag
sever
hemorrhag
organ
failur
dv
genom
posit
singlestrand
rna
molecul
encod
polyprotein
process
three
structur
protein
capsid
protein
c
membran
protein
envelop
protein
e
seven
nonstructur
ns
protein
involv
replic
pathogen
dv
enter
target
cell
via
receptormedi
endocytosi
traffic
via
endosom
acid
environ
trigger
fusion
viral
host
cell
membran
within
target
cell
viru
manipul
host
cell
membran
creat
optim
environ
assembl
replic
complex
subsequ
rna
amplif
virion
assembl
occur
surfac
endoplasm
reticulum
er
follow
bud
immatur
particl
er
lumen
immatur
virion
transport
transgolgi
network
matur
via
proteolyt
cleavag
final
releas
exocytosi
extracellular
medium
specif
antivir
treatment
dv
current
exist
avail
therapi
symptomat
administ
control
clinic
manifest
abil
diagnos
dv
infect
earli
stage
success
prognosi
result
complic
dengu
urgent
requir
improv
manag
patient
possibl
identif
protein
specif
present
plasma
onset
sever
symptom
may
ultim
lead
discoveri
new
prognost
biomark
despit
incomplet
understand
mechan
pathogen
sever
hypothes
formul
explain
diseas
process
patient
infect
dv
howev
lack
anim
model
capabl
reproduc
featur
human
diseas
hamper
identif
reliabl
paramet
indic
explain
predict
develop
sd
number
host
immun
compon
especi
antibodi
associ
pathogen
viral
infect
mechan
includ
antibodydepend
enhanc
secondari
infect
crossreact
protein
endotheli
cell
coagul
protein
immun
compon
includ
memori
tcell
innat
immun
effector
complement
factor
shown
modul
outcom
dv
nonstructur
protein
may
also
play
major
pathogen
role
interact
host
complement
protein
numer
studi
investig
associ
alter
level
circul
cytokineschemokin
dengu
sever
altern
strong
biolog
rational
investig
marker
implic
vascular
patholog
mani
marker
solubl
intercellular
adhes
solubl
vascular
cell
adhes
eselectin
thrombomodulin
identifi
seem
correl
diseas
sever
unfortun
clear
consensu
emerg
studi
predict
outcom
dengu
remain
challeng
search
robust
marker
remain
crucial
previou
studi
demonstr
patient
sd
higher
viremia
patient
df
addit
report
cuba
australia
suggest
circul
dv
may
becom
virul
passag
success
host
epidem
viru
cycl
viru
pathogen
strongli
link
host
metabol
assum
host
protein
interact
virion
reflect
patholog
statu
patient
therefor
present
studi
dvenrich
procedur
combin
sucros
gradient
ultracentrifug
polymerbas
techniqu
develop
differenti
proteom
analysi
plasma
pool
patient
df
sd
liquid
chromatographi
coupl
tandem
mass
spectrometri
lcmsm
object
identifi
viral
protein
host
protein
incorpor
virion
also
host
protein
interactar
associ
virion
identifi
marker
valid
quantit
elisa
use
sampl
dengu
patient
two
differ
geograph
region
possibl
role
coidentifi
host
protein
diseas
pathogen
potenti
protein
fingerprint
diseas
sever
patient
infect
dv
discuss
plasma
sampl
provid
universidad
industri
de
santand
bucaramanga
colombia
institut
pasteur
phnompenh
cambodia
sampl
collect
dengu
patient
part
retrospect
colombia
prospect
studi
cambodia
studi
review
approv
local
medic
ethic
committe
universidad
industri
de
santand
colombia
nation
ethic
committe
cambodia
perform
complianc
ethic
standard
set
declar
helsinki
patient
plasma
sampl
anonym
physic
examin
obtain
inform
consent
dr
villarcenteno
universidad
industri
de
santand
bucaramanga
colombia
dr
philipp
buchi
institut
pasteur
phnompenh
cambodia
grant
author
permiss
use
sampl
sampl
collect
onset
symptom
defervesc
case
classifi
primari
secondari
infect
physician
base
hemagglutin
assay
perform
differ
dv
serotyp
japanes
enceph
viru
serotyp
copi
number
determin
realtim
quantit
rtpcr
qrtpcr
dvneg
plasma
specimen
healthi
donor
obtain
french
nation
blood
bank
etabliss
du
sang
lyon
franc
dengu
sampl
test
presenc
viral
protein
use
elisa
biorad
marneslacoquett
franc
follow
manufactur
instruct
rna
extract
plasma
use
qiamp
viral
rna
kit
qiagen
hilden
germani
viremia
measur
use
qrtpcr
kit
primerdesign
southampton
uk
accord
manufactur
instruct
qrtpcr
perform
final
volum
contain
extract
rna
precis
onesteptm
qrtpcr
mastermix
dengu
primerprob
mix
assay
carri
use
roch
appli
scienc
switzerland
use
onestep
amplif
protocol
recommend
manufactur
cell
atcc
cultiv
dmem
supplement
decompl
fetal
calf
serum
iu
penicillin
mg
streptomycin
mm
lglutamin
invitrogen
paisley
uk
cell
infect
previous
describ
serotyp
dv
strain
thailand
gracious
provid
dr
v
barban
sanofipasteur
lyon
franc
subconflu
cell
cultur
approx
flask
incub
viru
dilut
serumfre
cultur
medium
variou
multipl
infect
moi
min
supernat
remov
cell
wash
pb
invitrogen
ml
fresh
complet
medium
ad
cell
day
cultur
supernat
harvest
clarifi
centrifug
g
min
follow
denatur
sd
samplebuff
novex
invitrogen
paisley
uk
denatur
polyacrylamid
gel
electrophoresi
page
polyacrylamid
gel
sdsmop
buffer
nupag
invitrogen
sampl
electrotransf
pvdf
membran
millipor
billerica
mt
usa
methanol
buffer
block
tween
skim
dri
milk
macon
franc
incub
anti
monoclon
antibodi
dilut
biomerieux
marcyl
etoil
franc
follow
horseradish
peroxidaselabel
conjug
dilut
pari
compiegn
franc
h
room
temperatur
rt
wash
tween
protein
reveal
use
supersign
west
dura
kit
thermo
scientif
rockford
il
usa
imag
use
imag
system
biorad
hercul
ca
usa
altern
gel
silverstain
electrophoresi
use
silverxpress
kit
life
technolog
paisley
uk
densitometri
analysi
carri
use
quantityon
softwar
biorad
five
millilit
preclarifi
plasma
pool
cf
tabl
ml
preclarifi
cell
cultur
supernat
centrifug
h
g
use
beckman
rotor
optima
ultracentrifug
beckman
fullerton
ca
usa
centrifug
pellet
dissolv
small
volum
cold
pb
euromedex
souffelweyersheim
franc
load
discontinu
sucros
gradient
constitut
ml
sucros
pb
ww
ml
sucros
pb
ww
centrifug
h
g
fraction
contain
virion
locat
interfac
two
sucros
solut
collect
dilut
tenfold
cold
pb
centrifug
h
g
pellet
resuspend
cold
pb
centrifug
step
perform
ultracentrifug
complement
addit
purif
step
use
biotechsupportgroup
monmouth
usa
water
insolubl
elastomer
polyelectrolyt
develop
captur
recoveri
virus
accord
manufactur
instruct
briefli
mn
buffer
mm
me
ph
mm
nacl
ad
resuspend
pellet
obtain
ultracentrifug
mixtur
incub
min
rt
centrifug
g
min
supernat
discard
pellet
rins
three
time
mn
buffer
final
viral
fraction
separ
polym
heat
min
sdsbuffer
novex
invitrogen
final
centrifug
step
g
supernat
harvest
store
immunoblot
lcmsm
analysi
follow
experi
conduct
edyp
laboratori
edypservic
cea
grenobl
franc
virionenrich
prepar
load
polyacrylamid
gel
electrophores
protein
enter
gel
band
contain
protein
manual
excis
wash
three
time
buffer
contain
acetonitril
dri
use
acetonitril
gel
piec
rehydr
min
dark
wash
incub
modifi
sequencinggrad
trypsin
solut
promega
madison
wi
usa
mm
overnight
peptid
extract
gel
band
via
three
sequenti
extract
step
min
acetonitril
formic
acid
acetonitril
extract
pool
vacuum
dri
resuspend
solut
contain
acetonitril
trifluoroacet
acid
quantiti
normal
peptid
analyz
nanoliquid
chromatographi
coupl
tandem
mass
spectrometri
ultim
dionex
sunnyval
ca
ltqorbitrap
velospro
thermofish
scientif
rockford
il
usa
data
acquir
use
xcalibur
softwar
thermofish
scientif
process
automat
use
mascot
daemon
softwar
version
matrix
scienc
boston
usa
protein
mascot
score
higher
p
select
analysi
mascot
score
measur
reliabl
identif
higher
score
better
identif
order
elimin
fals
match
incorrect
protein
identif
consecut
search
concaten
swissprot
trembldecoy
databas
version
decoy
databas
respect
homo
sapien
taxonomi
entri
perform
sampl
use
mascot
softwar
matrix
scienc
irma
softwar
use
filter
result
achiev
fals
posit
rate
lower
ingel
digest
lcmsm
analysi
perform
twice
sampl
ingenu
pathway
analysi
ipa
softwar
ingenu
system
redwood
citi
ca
usa
use
investig
interact
among
host
protein
identifi
interact
pathway
gener
observ
potenti
direct
indirect
relationship
among
protein
differenti
express
df
sd
sampl
commerci
elisa
uscn
wuhan
china
target
potenti
sever
marker
use
measur
duplic
level
protein
individu
df
sd
plasma
specimen
use
protocol
recommend
manufactur
test
standard
curv
establish
serial
dilut
calibr
provid
kit
determin
protein
concentr
optic
densiti
valu
determin
nm
use
micropl
reader
eon
biotek
vinooski
vt
usa
statist
analysi
u
test
chisquar
test
receiv
oper
curv
analysi
perform
use
graphpad
prism
softwar
graphpad
softwar
san
diego
ca
usa
chisquar
test
use
examin
differ
demograph
clinic
characterist
patient
assess
potenti
confound
variabl
comparison
continu
variabl
perform
use
u
test
appli
unknown
distribut
two
small
set
observ
n
comparison
proport
perform
use
chisquar
test
p
consid
signific
plasma
obtain
patient
df
sd
pool
creat
two
sampl
tabl
plasma
sampl
use
step
came
colombian
patient
secondari
dv
serotyp
infect
collect
onset
symptom
develop
sever
symptom
classif
infect
secondari
infect
degre
sever
base
review
patient
medic
record
medic
record
estim
sever
base
criteria
df
dhf
grade
dengu
haemorrhag
fever
minor
haemorrhag
consid
classicdengu
sever
dhf
grade
iiiiv
dss
dengu
shock
syndrom
consid
sever
dengu
medic
record
compil
detail
platelet
blood
cell
count
transaminas
level
presenceabs
warn
sign
persist
vomit
abdomin
haemorrhag
sign
petechia
ecchymosi
shock
sign
cold
extrem
help
patient
classif
physician
proport
sampl
male
patient
higher
df
pool
sd
pool
age
patient
mean
year
number
day
sampl
collect
onset
symptom
mean
approxim
day
similar
two
group
comorbid
report
patient
either
group
individu
plasma
sampl
confirm
viremia
pool
estim
use
commerci
qrtpcr
kit
patient
posit
dv
indic
sampl
collect
acut
phase
diseas
averag
number
rna
copi
per
ml
sampl
df
sd
pool
respect
techniqu
base
ultracentifug
step
follow
concentr
use
commerci
waterinsolubl
elastomer
polyelectrolyt
special
engin
captur
recoveri
virus
step
creat
obtain
fraction
plasma
enrich
dv
particl
initi
techniqu
develop
use
cell
cultur
supernat
cell
harvest
five
day
infect
dv
moi
sampl
obtain
step
purif
process
step
step
analyz
western
blot
use
anti
monoclon
antibodi
fig
posit
signal
correspond
monomer
kda
dimer
e
protein
kda
observ
dvinfect
sampl
becam
intens
step
fig
step
puriti
step
sampl
assess
electrophoresi
use
denatur
page
silverstain
fig
bovin
serum
albumin
bsa
intens
protein
band
approxim
kda
observ
sampl
purif
purifi
lane
howev
band
almost
absent
final
purifi
sampl
step
lane
small
number
band
detect
purifi
sampl
densitometri
indic
protein
complex
purifi
sampl
reduc
roughli
compar
unpurifi
sampl
presenc
intact
viral
particl
also
confirm
electron
microscopi
perform
ezu
laboratori
claud
bernard
villeurbann
franc
neg
stain
virion
could
visual
purifi
sampl
obtain
supernat
cell
infect
moi
fig
viral
membran
includ
e
spike
visibl
spike
observ
virion
surfac
probabl
due
slightli
basic
ph
ph
pbsbuffer
solut
use
centrifug
electron
microscopi
virion
tend
aggreg
cluster
viral
particl
seen
imag
taken
lower
magnif
littl
background
signal
observ
around
virion
cluster
follow
twostep
purif
process
moi
sampl
also
analyz
nanolc
msm
structur
viral
protein
identifi
tabl
e
protein
peptid
larg
repres
peptid
singl
peptid
sequenc
coverag
e
protein
repres
entir
protein
protein
part
extern
viral
layer
along
e
protein
identifi
three
time
singl
peptid
coverag
protein
sequenc
pr
peptid
capsid
also
identifi
one
peptid
conclus
combin
ultracentrifug
viraffin
polym
yield
fraction
consider
reduc
protein
complex
contain
larg
quantiti
envelop
virion
techniqu
appli
pool
plasma
sampl
obtain
colombian
patient
tabl
purif
prepar
analyz
western
blot
use
monoclon
antibodi
direct
e
viral
protein
fig
sd
pool
exampl
strong
signal
correspond
monomer
kda
dimer
e
protein
kda
observ
e
protein
detect
purifi
plasma
obtain
healthi
individu
test
mockcontrol
identifi
protein
present
purifi
sampl
compar
composit
nanolcmsm
conduct
purifi
df
sd
plasma
pool
experi
also
perform
purifi
mockcontrol
sampl
determin
host
background
quantiti
total
protein
analyz
sampl
experi
perform
independ
twice
viral
host
peptid
identifi
purifi
pool
plasma
sampl
patient
df
sd
one
peptid
correspond
viral
envelop
protein
detect
twice
sd
sampl
peptid
gwgngcgllfgk
also
identifi
purifi
dvinfect
supernat
tabl
remov
mockcontrol
background
remain
peptid
identifi
df
sd
sampl
analyz
order
consolid
result
obtain
nanolc
msm
protein
varianc
averag
number
peptid
lower
select
host
protein
met
criterion
sddf
peptid
ratio
calcul
protein
see
addit
file
highest
sddf
ratio
obtain
esteras
sddf
peptid
ratio
vitamin
kdepend
protein
ratio
lowest
ratio
obtain
spectrin
ratio
six
protein
identifi
sd
sampl
consequ
sddf
ratio
could
calcul
protein
ingenu
pathway
analysi
ipa
conduct
elucid
specif
pathway
associ
identifi
host
protein
specif
locat
function
pathway
attribut
ipa
protein
promin
repres
pathway
illustr
fig
ipa
diagram
show
highest
pvalu
attribut
acut
phase
respons
signal
pvalu
lp
lxrrxr
activ
pathway
lp
complement
system
lp
coagul
system
lp
extrins
prothrombin
activ
pathway
lp
pvalu
indic
likelihood
focu
gene
network
found
pathway
random
chanc
alon
although
repres
lesser
degre
three
pathway
relat
host
protein
involv
dv
cell
cycl
clathrinmedi
endocytosi
signal
lp
caveolarmedi
endocytosi
signal
lp
viru
entri
via
endocyt
pathway
lp
also
identifi
identifi
pathway
includ
integrin
lp
paxillin
signal
lp
correspond
protein
involv
cellmatrix
interact
celltocel
commun
figur
also
illustr
ratio
identifi
protein
canon
pathway
higher
proport
protein
map
complement
system
ratio
coagul
system
ratio
extrins
prothrombin
activ
pathway
ratio
pathway
ratio
ipa
softwar
also
use
investig
possibl
interact
among
identifi
protein
assess
represent
identifi
protein
acut
phase
respons
signal
complement
system
coagul
system
prothrombin
activ
see
addit
file
twenti
secret
protein
identifi
ipa
part
acut
phase
respons
signal
pathway
activ
macrophag
endotheli
cell
upon
infect
inflamm
overrepres
pool
sd
plasma
sampl
compar
pool
df
plasma
sampl
thirteen
complement
compon
protein
also
overrepres
sd
plasma
high
number
peptid
identifi
particular
complement
factor
complement
factor
b
cfb
involv
complement
altern
pathway
identifi
pool
sd
plasma
sampl
protein
enrich
pool
df
plasma
sampl
extrins
intrins
prothrombin
activ
pathway
part
coagul
system
major
protein
involv
fibrinogenfibrin
cascad
ie
protein
overrepres
sd
sampl
compar
df
sampl
overal
network
analysi
also
provid
evid
strong
link
three
pathway
coagul
factor
protein
locat
interfac
coagul
system
complement
system
see
addit
file
valid
mass
spectrometri
data
level
select
host
protein
assess
quantit
elisa
virusenrich
fraction
individu
plasma
sampl
df
sd
patient
elisa
protein
sddf
ratio
higher
lower
select
see
addit
file
criteria
number
peptid
identifi
sd
sampl
avail
commerci
elisa
kit
also
consid
protein
ribosom
protein
access
number
ratio
histon
access
number
ratio
deem
relev
enough
studi
consequ
test
protein
readili
found
high
concentr
plasma
known
frequent
contamin
proteom
experi
immunoglobulin
heavi
chain
access
number
ratio
test
final
nonexhaust
list
protein
assay
establish
protein
ceruloplasmin
cp
vitamin
kdepend
protein
complement
factor
properdin
antithrombin
iii
secretori
compon
complement
factor
complement
factor
angiotensin
factor
antifactor
viii
serum
amyloid
pcompon
thrombospondin
gelsolin
platelet
factor
complement
factor
complement
factor
b
moesin
complement
factor
apolipoprotein
von
willebrand
factor
also
test
protein
first
quantifi
virusenrich
fraction
individu
plasma
sampl
obtain
df
sd
patient
colombian
cohort
elisa
signal
level
sampl
close
background
level
purifi
mockcontrol
sampl
result
interpret
investig
potenti
interact
protein
virion
fresh
plasma
incub
variou
time
purifi
viral
particl
chang
protein
concentr
incub
assess
elisa
experi
perform
protein
cp
show
signific
signal
chang
observ
protein
whatev
condit
test
data
shown
viru
prepar
probabl
concentr
enough
induc
signific
variat
host
protein
concentr
furthermor
plasmat
concentr
four
protein
high
significantli
affect
interact
viru
coat
micropl
elisa
perform
whole
plasma
sampl
obtain
colombian
patient
tabl
colombian
patient
patient
secondari
infect
associ
variou
dv
serotyp
sampl
collect
onset
defervesc
day
malefemal
sex
ratio
age
similar
group
patient
df
sd
sampl
confirm
posit
dv
qrtpcr
viral
protein
use
commerci
elisa
comorbid
record
patient
among
protein
test
cp
differ
plasma
concentr
df
sd
patient
averag
concentr
higher
patient
sd
patient
df
p
moreov
varianc
two
group
significantli
differ
p
protein
concentr
consid
higher
sd
patient
p
cp
differ
two
group
signific
p
largest
differ
observ
higher
concentr
patient
df
p
fig
confirm
relev
cp
potenti
marker
differenci
df
sd
plasma
sampl
patient
acut
dengu
cambodia
anoth
dengueendem
area
test
colombian
patient
cambodian
patient
classifi
local
physician
use
classif
present
studi
patient
classifi
df
dhf
grade
consid
classic
dengu
patient
classifi
dhf
grade
iii
iv
consid
sever
dengu
clinic
data
collect
includ
detail
platelet
count
transaminas
level
blood
cell
count
biochemistri
cholesterol
triglycerid
ultrasound
imageri
hemorrhag
sign
petechia
ecchymosi
presenceor
absenc
warn
sign
persist
vomit
abdomin
plasma
leakag
shock
sign
cold
extrem
main
characterist
cambodian
patient
detail
tabl
cambodian
patient
mean
age
patient
cambodia
yearsold
lower
colombian
patient
malefemal
ratio
df
sd
group
similar
cambodian
patient
infect
serotyp
virus
plasma
sampl
collect
approxim
day
onset
symptom
acut
sampl
also
discharg
hospit
discharg
sampl
contrast
sampl
obtain
colombian
patient
elisa
show
level
cp
significantli
differ
df
sd
patient
cambodian
cohort
see
addit
file
howev
concentr
p
p
acut
phase
significantli
differ
df
sd
plasma
fig
concentr
df
patient
lower
sd
patient
contrast
concentr
higher
df
patient
sd
patient
sd
patient
show
signific
differ
healthi
control
n
two
marker
time
discharg
concentr
tend
declin
back
level
observ
control
receiv
oper
characterist
roc
curv
compar
sensit
versu
specif
across
rang
valu
roc
curv
use
assess
discriminatori
abil
marker
area
roc
curv
auc
anoth
measur
test
perform
auc
quantifi
overal
abil
test
discrimin
individu
df
sd
perfect
test
zero
fals
posit
zero
fals
neg
auc
roc
curv
analysi
use
determin
auc
specificitysensit
valu
prognost
biomark
diseas
sever
cambodian
acut
patient
dengu
roc
curv
indic
good
discrimin
df
sd
auc
highest
specificitysensit
valu
obtain
use
model
summar
tabl
sensit
specif
exceed
sensit
reach
specif
drop
dengu
viral
infect
preval
tropic
subtrop
area
associ
substanti
morbid
mortal
pathogenesi
dengu
remain
unclear
variou
proteom
approach
use
character
hostprotein
chang
dv
infect
identifi
prognost
biomark
diseas
sever
sever
studi
conduct
cell
infect
vitro
studi
plasma
specimen
identifi
number
candid
biomark
dynam
rang
plasma
protein
larg
order
magnitud
abund
protein
total
number
constitut
plasmat
protein
mass
identif
biomark
present
low
concentr
major
challeng
proteom
studi
deal
plasma
howev
proteom
techniqu
constantli
improv
assess
low
abund
plasma
protein
virus
facilit
replic
propag
subvert
host
cellular
pathway
process
constantli
adapt
modul
host
environ
envelop
virus
abl
incorpor
numer
host
protein
viru
particl
well
hostderiv
viral
envelop
genom
rna
virus
encod
small
number
protein
must
reli
host
protein
infect
interact
viru
host
may
unforeseen
consequ
depend
viremia
level
host
genet
background
relev
factor
host
protein
incorpor
virion
either
randomli
present
site
bud
specif
result
interact
viral
protein
function
signific
host
protein
associ
viral
particl
remain
thoroughli
investig
howev
like
interact
contribut
pathogen
disturb
metabol
host
cell
instanc
incorpor
cellular
protein
integrin
hla
class
ii
protein
affect
abil
infect
host
cell
contribut
immunopathogenesi
viroproteom
analys
alreadi
conduct
dna
virus
rna
virus
retrovirus
paramyxovirus
coronavirus
flavivirus
studi
proven
mani
cellular
protein
incorpor
virion
associ
viral
membran
usual
prior
ms
analysi
proteas
hydrolysi
combin
ultracentrifug
remov
host
protein
may
copurifi
virion
present
studi
aim
character
host
protein
interact
viral
membran
protein
particl
enzymat
hydrolysi
protein
outsid
virion
could
perform
therefor
new
techniqu
combin
ultracentrifug
waterinsolubl
polyelectrolytebas
enrich
develop
enabl
proteom
character
fraction
human
plasma
enrich
viru
particl
deplet
host
protein
predominantli
express
plasma
previou
studi
measur
viremia
demonstr
patient
sd
higher
viremia
patient
df
higher
viremia
may
lead
biosynthesi
virion
alter
host
protein
composit
may
reflect
increas
level
cellular
stress
subtl
chang
assembl
pathway
host
protein
may
packag
viru
particl
along
viral
compon
incorpor
viral
membran
altern
simpli
copurifi
along
virion
protein
may
potenti
fingerprint
viru
assembl
pathway
may
also
play
role
viral
pathogen
nano
lcmsm
use
studi
analyz
protein
composit
virionenrich
sampl
purifi
plasma
pool
protein
higher
averag
number
peptid
sd
sampl
df
control
sampl
suggest
presenc
greater
amount
protein
associ
virus
purifi
plasma
patient
sd
convers
protein
mainli
identifi
sampl
purifi
df
plasma
pool
interestingli
identifi
host
protein
belong
three
main
pathway
complement
system
coagul
system
acut
respons
signal
pathway
complement
system
play
import
role
innat
adapt
immun
respons
first
line
defens
infecti
agent
modul
b
tcell
respons
flaviviru
infect
excessivelyactiv
complement
protein
report
induc
deleteri
exacerb
inflammatori
respons
recent
shown
level
complement
protein
posit
correl
sever
dengu
indonesian
patient
coagul
process
blood
chang
liquid
gel
coagul
requir
stop
blood
loss
enabl
subsequ
repair
damag
vessel
hemorrhag
one
major
symptom
sd
probabl
caus
vasculopathi
defici
coagul
fibrinolysi
normal
vascular
endothelium
produc
inhibitor
coagul
fibrinolysi
hemostasi
impair
endothelium
stimul
excess
level
cytokin
pathogen
may
turn
result
thrombosi
bleed
acut
phase
respons
correspond
inflammatori
respons
observ
respons
infect
tissu
injuri
immunolog
disord
mainli
character
increas
level
inflammatori
factor
chang
protein
composit
plasma
interestingli
chang
inhibit
complement
activ
interconnect
coagul
process
complement
cascad
report
mani
author
deregul
one
system
result
clinic
manifest
diseas
inflammatori
complic
previou
studi
differentiallyexpress
gene
associ
immun
respons
identifi
microarray
analysi
peripher
blood
mononuclear
cell
isol
colombian
children
dengu
fever
dengu
hemorrhag
fever
result
indic
complement
numer
cytokin
deregul
patient
denguehemorrhag
fever
chang
may
enhanc
diseas
sever
disturb
coagul
induc
endotheli
cell
damag
anoth
recent
studi
sera
indian
patient
df
compar
healthi
control
use
associ
maldi
toftof
ms
author
report
dv
infect
led
alter
express
multipl
serum
protein
involv
complement
cascad
blood
coagul
acut
phase
respons
signal
provid
clue
regard
pathogenesi
host
immun
respons
dv
infect
complement
system
coagul
system
acut
respons
signal
pathway
strongli
interconnect
share
protein
whose
express
modul
infect
relat
inflammatori
process
innat
immun
respons
act
upstream
activ
adapt
immun
respons
express
deregul
protein
could
induc
deleteri
effect
endotheli
cell
hand
none
seven
complement
protein
test
elisa
show
differ
concentr
level
sd
df
acut
sampl
minim
potenti
role
protein
dengu
pathogenesi
least
earli
phase
diseas
sever
author
report
proteom
analysi
sampl
patient
dengu
use
differ
approach
knowledg
studi
first
assess
protein
differenti
present
virusenrich
fraction
purifi
plasma
specimen
obtain
patient
acut
stage
dv
infect
unabl
confirm
protein
identifi
lcmsm
directli
associ
viral
particl
neither
elisa
conduct
virion
purifi
plasma
electron
microscopi
use
specif
goldlabel
antibodi
succeed
yield
reliabl
result
consequ
discard
possibl
host
protein
identifi
studi
may
contamin
copurifi
reproduc
viral
particl
elisa
carri
individu
plasma
specimen
colombian
cohort
indic
trend
toward
higher
level
cp
patient
sd
compar
patient
df
cp
acut
phase
protein
ferroxidas
involv
iron
metabol
elev
level
cp
gener
observ
inflamm
complement
protein
interact
begin
complement
cascad
antiapoptot
factor
promot
tumor
growth
facilit
cell
adhes
probabl
via
interact
cell
surfac
lectin
cadherin
associ
protein
diseas
sever
dengu
remain
explor
interestingli
recent
paper
mention
interest
marker
diseas
sever
respiratori
syncyti
viru
infect
children
elisa
also
show
concentr
higher
plasma
sampl
colombian
patient
df
patient
sd
small
cytokin
releas
platelet
promot
blood
coagul
moder
effect
heparinlik
molecul
also
play
role
wound
repair
inflamm
alter
platelet
function
associ
plasma
leakag
one
major
featur
sever
diseas
patient
dengu
recent
demonstr
dv
replic
produc
infecti
viru
platelet
srichaikul
et
al
demonstr
level
increas
acut
phase
shock
nonshock
dhf
children
difficult
compar
result
result
present
strict
correspond
patient
classif
use
srichaikul
et
al
classif
use
present
work
interestingli
among
six
protein
involv
coagul
sddf
peptid
ratio
higher
lower
see
addit
file
one
confirm
elisa
significantli
less
concentr
sd
acut
patient
plasma
trend
observ
elisa
colombian
patient
also
confirm
cambodian
patient
test
differ
time
point
cours
diseas
show
marker
evolv
time
tend
process
heal
get
close
protein
concentr
found
healthi
patient
overabund
df
acut
patient
remain
surprisingli
low
sd
patient
level
remain
similar
control
individu
previous
propos
interact
vasculatur
involv
thrombu
format
site
vascular
injuri
murin
studi
suggest
may
overal
salutari
effect
sepsi
therefor
basal
level
express
acut
phase
dv
infect
could
interest
marker
futur
sever
dengu
sever
dengu
modul
multipl
risk
factor
age
genet
background
nutrit
statu
host
well
genotyp
serotyp
viru
factor
could
explain
differ
concentr
specif
marker
observ
plasma
sampl
colombian
cambodian
patient
exampl
sd
southeast
asia
mainli
observ
children
wherea
adult
predominantli
affect
south
america
consequ
result
extrapol
caution
differ
geograph
area
differ
demograph
group
conclus
describ
develop
novel
techniqu
dvenrich
complex
biolog
fluid
base
centrifug
combin
waterinsolubl
polyelectrolytebas
techniqu
subsequ
proteom
analys
found
evid
identifi
host
protein
specif
associ
virion
howev
purif
techniqu
enabl
analysi
plasma
fraction
enrich
virion
abund
plasma
protein
remov
host
protein
character
studi
may
potenti
reflect
dv
infect
disturb
function
cellular
proteom
regard
studi
requir
assess
prognost
valu
host
protein
associ
inflamm
complement
cascad
coagul
diseas
sever
analysi
addit
biolog
sampl
patient
infect
dv
analysi
select
identifi
protein
use
elisa
identifi
two
host
protein
signific
prognost
valu
classifi
patient
dengu
like
develop
sd
prospect
studi
warrant
confirm
valid
prognost
valu
potenti
biomark
diseas
sever
larger
cohort
patient
varieti
dengueendem
area
around
globe
data
support
find
materi
avail
upon
request
freder
bedin
biomerieux
sa
chemin
de
l
orm
marci
l
etoil
franc
